Skip to main content

Table 1 Demographic and disease characteristics of all study subjects

From: Statin indication according to the 2019 World Health Organization cardiovascular disease risk charts and carotid ultrasound in Mexican mestizo rheumatoid arthritis patients

Variable

RA patients (n = 157)

Demographic characteristics

Age (years), mean ± SD

55.3 ± 9.4

Female, n (%)

149 (94.9)

BMI (kg/m2) mean ± SD

29.37 ± 5.68

Systolic blood pressure, mean ± SD

123 ± 17

Traditional cardiovascular risk factors

Dyslipidemia, n (%)

36 (22.9)

Hypertension, n (%)

54 (34.4)

Obesity, n (%)

60 (38.2)

T2DM, n (%)

25 (15.9)

Active smokers, n (%)

15 (9.6)

Former smokers, n (%)

19 (12.1)

Antihypertensive treatment, n (%)

48 (30.6)

Lipid profile

Total cholesterol (mg/dl), mean ± SD

177.6 ± 34.1

Triglycerides (mg/dl), median (p25–p75)

128 (92.1–163.8)

LDL-C (mg/dl), mean ± SD

96 ± 29.1

HDL-C (mg/dl), median (p25–p75)

51.8 (43.9–61.9)

Disease characteristics

Disease duration (years), median (p25–p75)

8.4 (3.7–16.2)

DAS28-CRP, mean ± SD

3.45 (± 1.37)

Disease activity classification (DAS28-CRP)

 Remission, n (%)

50 (31.2)

 Low, n (%)

20 (12.7)

 Moderate, n (%)

65 (41.4)

 High, n (%)

22 (14)

HAQ, median (p25-p75)

0.38 (0–1.06)

Positive RF, n (%)

132 (84.1)

Positive anti-CCP, n (%)

99 (63.1)

CRP (mg/dl), median (p25–p75)

0.81(0.5–1.25)

ESR (mm/h), median (p25–p75)

23 (15–37)

Treatment

MTX, n (%)

123 (78.3)

Glucocorticoids, n (%)

87 (55.4)

bDMARD, n (%)

15 (9.6)

  1. RA rheumatoid arthritis, BMI body mass index, T2DM type 2 diabetes mellitus, LDL-C low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, DAS28-CRP disease activity score using 28 joints and C-reactive protein, HAQ health assessment questionnaire, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MTX methotrexate, bDMARD biologic disease-modifying antirheumatic drugs